Gregg Gonsalves, PhD
Associate Professor of Epidemiology (Microbial Diseases)DownloadHi-Res Photo
Cards
Additional Titles
Associate (Adjunct) Professor of Law, Yale Law School
Affiliated Faculty, Program in Addiction Medicine
Co-Director, Global Health Justice Partnership
Affiliated Faculty, Yale Institute for Global Health
Contact Info
About
Titles
Associate Professor of Epidemiology (Microbial Diseases)
Associate (Adjunct) Professor of Law, Yale Law School; Affiliated Faculty, Program in Addiction Medicine; Co-Director, Global Health Justice Partnership; Affiliated Faculty, Yale Institute for Global Health
Biography
Gregg Gonsalves is an expert in policy modeling on infectious disease and substance use, as well as the intersection of public policy and health equity. His research focuses on the use of quantitative models for improving the response to epidemic diseases. For more than 30 years, he worked on HIV/AIDS and other global health issues with several organizations, including the AIDS Coalition to Unleash Power, the Treatment Action Group, Gay Men’s Health Crisis, and the AIDS and Rights Alliance for Southern Africa. He is a 2011 graduate of Yale College and received his PhD from Yale Graduate School of Arts and Sciences/School of Public Health in 2017. He is currently the public health correspondent for The Nation. He is a 2018 MacArthur Fellow.
Appointments
Epidemiology of Microbial Diseases
Associate Professor on TermPrimarySchool of Law
Research ScholarSecondarySchool of Law
LecturerSecondarySchool of Law
Associate Professor AdjunctSecondary
Other Departments & Organizations
Education & Training
- PhD
- Yale University, Public Health (2017)
- BS
- Yale College, Ecology and Evolutionary Biology (2011)
Research
Overview
Medical Research Interests
Causality; Computer Simulation; Decision Making; Drug Approval; Drug Users; Hepatitis C; HIV; Operations Research; Political Systems; Prisoners; Public Policy; Social Determinants of Health; Social Justice; Social Medicine; Tuberculosis; United States Food and Drug Administration
Public Health Interests
Community Health; Global Health; Health Care Management; Health Policy; HIV/AIDS; Infectious Diseases; Modeling; Health Equity, Disparities, Social Determinants and Justice; COVID-19
ORCID
0000-0002-5789-9841
Research at a Glance
Yale Co-Authors
Frequent collaborators of Gregg Gonsalves's published research.
Publications Timeline
A big-picture view of Gregg Gonsalves's research output by year.
Research Interests
Research topics Gregg Gonsalves is interested in exploring.
A. David Paltiel, MBA, PhD
Alexandra Savinkina, MSPH
Joseph Ross, MD, MHS
Thomas Thornhill IV
Haidong Lu, PhD
Virginia Pitzer, ScD
99Publications
1,632Citations
Public Policy
United States Food and Drug Administration
Computer Simulation
Decision Making
Hepatitis C
Prisoners
Publications
Featured Publications
Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study
Savinkina A, Bilinski A, Fitzpatrick M, Paltiel AD, Rizvi Z, Salomon J, Thornhill T, Gonsalves G. Estimating deaths averted and cost per life saved by scaling up mRNA COVID-19 vaccination in low-income and lower-middle-income countries in the COVID-19 Omicron variant era: a modelling study. BMJ Open 2022, 12: e061752. PMID: 36100306, PMCID: PMC9471205, DOI: 10.1136/bmjopen-2022-061752.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsLow-income countriesIncome countriesDeath avertedHigh-income nationsStatistical lifeAvertable deathsIncome nationsCOVID-19 deathsReasonable investmentHigh costKey inputCountriesParameter estimatesAvertedCostSensitivity analysisUniversal vaccinationGlobal vaccinationMRNA COVID-19 vaccinationNationsInvestmentPrimary vaccine seriesLow vaccine effectivenessCOVID-19 vaccinationPublic dataSurveillance for endemic infectious disease outbreaks: Adaptive sampling using profile likelihood estimation
Fairley M, Rao IJ, Brandeau ML, Qian GL, Gonsalves GS. Surveillance for endemic infectious disease outbreaks: Adaptive sampling using profile likelihood estimation. Statistics In Medicine 2022, 41: 3336-3348. PMID: 35527474, PMCID: PMC9283243, DOI: 10.1002/sim.9420.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2024
Modelling vaccination approaches for mpox containment and mitigation in the Democratic Republic of the Congo
Savinkina A, Kindrachuk J, Bogoch I, Rimoin A, Hoff N, Shaw S, Pitzer V, Mbala-Kingebeni P, Gonsalves G. Modelling vaccination approaches for mpox containment and mitigation in the Democratic Republic of the Congo. The Lancet Global Health 2024 PMID: 39393385, DOI: 10.1016/s2214-109x(24)00384-x.Peer-Reviewed Original ResearchAltmetricIntegrating testing volume into bandit algorithms for infectious disease surveillance
Warren J, Prunas O, Paltiel A, Thornhill T, Gonsalves G. Integrating testing volume into bandit algorithms for infectious disease surveillance. Journal Of The Royal Statistical Society Series A (Statistics In Society) 2024, qnae090. DOI: 10.1093/jrsssa/qnae090.Peer-Reviewed Original ResearchAltmetricA Reference framework for integrating advanced algorithms into decision support in a public health emergency
Malloy S, Rayo M, Quam M, Gonsalves G, Kline D. A Reference framework for integrating advanced algorithms into decision support in a public health emergency. Annals Of Epidemiology 2024, 97: 74. DOI: 10.1016/j.annepidem.2024.07.092.Peer-Reviewed Original ResearchThe Evolution of Selection Bias in the Recent Epidemiologic Literature—A Selective Overview
Lu H, Howe C, Zivich P, Gonsalves G, Westreich D. The Evolution of Selection Bias in the Recent Epidemiologic Literature—A Selective Overview. American Journal Of Epidemiology 2024, kwae282. PMID: 39136207, DOI: 10.1093/aje/kwae282.Peer-Reviewed Original ResearchCitationsAltmetricDéjà Vu All Over Again — Refusing to Learn the Lessons of Covid-19
Sinha M, Parmet W, Gonsalves G. Déjà Vu All Over Again — Refusing to Learn the Lessons of Covid-19. New England Journal Of Medicine 2024, 391: 481-483. PMID: 39047237, DOI: 10.1056/nejmp2406427.Peer-Reviewed Original ResearchAltmetricProjecting the Potential Clinical and Economic Impact of Human Immunodeficiency Virus Prevention Resource Reallocation in Tennessee
Borre E, Ahonkhai A, Chi K, Osman A, Thayer K, Person A, Weddle A, Flanagan C, Pettit A, Closs D, Cotton M, Agwu A, Cespedes M, Ciaranello A, Gonsalves G, Hyle E, Paltiel A, Freedberg K, Neilan A. Projecting the Potential Clinical and Economic Impact of Human Immunodeficiency Virus Prevention Resource Reallocation in Tennessee. Clinical Infectious Diseases 2024, ciae243. PMID: 38913762, DOI: 10.1093/cid/ciae243.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCenters for Disease Control and PreventionIncrease HIV testingHuman immunodeficiency virus testingHuman immunodeficiency virusPriority populationsPrEP provisionCare linkageHIV testingPrevention fundingSurvivors of sex traffickingPregnant peopleTransgender womenLife yearsCondom useHIV prevention fundsUS Centers for Disease Control and PreventionDisease Control and PreventionBaseline condom useControl and PreventionReduced condom useHuman immunodeficiency virus transmissionHeterosexual Black womenPreexposure prophylaxisHIV transmissionBlack womenThe surge of mpox in Africa: a call for action
Nachega J, Sam-Agudu N, Ogoina D, Mbala-Kingebeni P, Ntoumi F, Nakouné E, Njouom R, Lewis R, Gandhi M, Rosenthal P, Rawat A, Wilson L, Kindrachuk J, Liesenborghs L, Mills E, Preiser W, Rimoin A, Sullivan N, Peeters M, Delaporte E, Baxter C, Harrison L, Hermans M, Mohr E, Gonsalves G, Ndembi N, Zumla A, Muyembe-Tamfum J, Consortium M. The surge of mpox in Africa: a call for action. The Lancet Global Health 2024, 12: e1086-e1088. PMID: 38735300, DOI: 10.1016/s2214-109x(24)00187-6.Peer-Reviewed Original ResearchCitationsAltmetricComparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States
Park H, Gonsalves G, Tan S, Kelly J, Rutherford G, Wachter R, Schechter R, Paltiel A, Lo N. Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. Nature Communications 2024, 15: 1883. PMID: 38448400, PMCID: PMC10917753, DOI: 10.1038/s41467-024-45549-9.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSevere COVID-19Risk of severe COVID-19COVID-19 booster vaccinationBooster vaccinationHigh-risk populationAbsolute annual riskWaning of protectionImmunocompromised populationsFrequent boostingOlder age groupsAnnual boosterImmune evasionImmunocompromised personsPublic health needsPublic health guidanceRisk groupsFrequent boostersImmune statusRisk factorsFrequency of booster vaccinationHealth needsHealth guidanceCompare frequenciesAge groupsVaccine
Academic Achievements & Community Involvement
honor MacArthur Fellowship
National AwardJohn D. and Catherine T. MacArthur FoundationDetails10/04/2018United States
News & Links
News
- October 29, 2024Source: Medscape
Researchers Deploy Technology to Find High-Risk HIV Populations
- October 16, 2024
Vaccinating children for mpox would significantly reduce deaths in the DRC
- September 17, 2024
YSPH researchers launch major initiative to improve HIV outbreak detection among people who use drugs
- August 30, 2024Source: The Guardian
U.S. repeating Covid mistakes with bird flu as spread raises alarm, experts say
Get In Touch
Contacts
Locations
Public Health Modeling Unit
Academic Office
350 George Street, Ste 3rd Floor
New Haven, CT 06511